Three-gene immunohistochemical panel predicts progression and unfavorable prognosis in esophageal squamous cell carcinoma

被引：2

作者：

Yu, Jie ^{[1
,2
,3
]}

Zheng, Yi ^{[4
]}

Han, Xue Ping ^{[1
,2
]}

Peng, Hao ^{[1
,2
]}

Pang, Li Juan ^{[1
,2
]}

Li, Feng ^{[1
,2
]}

Chen, Yunzhao ^{[3
]}

Cui, Xiaobin ^{[1
,2
]}

机构：

[1] Shihezi Univ, Dept Pathol, Sch Med, Shihezi 832002, Peoples R China

[2] Shihezi Univ, Key Lab Xinjiang Endem & Ethn Dis, Sch Med, Shihezi 832002, Peoples R China

[3] Peoples Hosp Suzhou Natl Hitech Dist, Dept Pathol, Suzhou 215010, Peoples R China

[4] Shihezi Univ, Affiliated Hosp 1, Dept Gastroenterol, Sch Med, Shihezi 832002, Peoples R China

来源：

HUMAN PATHOLOGY | 2019年 / 88卷

基金：

中国国家自然科学基金;

关键词：

Esophageal squamous cell carcinoma; Protein panel; Immunohistochemistry; Risk stratification; Prognosis evaluation; EXPRESSION; CANCER; PLCE1;

D O I：

10.1016/j.humpath.2018.11.027

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Esophageal squamous cell carcinoma (ESCC) is a highly invasive disease with a poor long-term survival rate. Although there has been progress in understanding the pathogenesis of ESCC, there are currently no molecular biomarkers that are used in routine clinical practices to determine prognosis. Therefore, the aim of this study was to determine a small immunohistochemical panel that could predict the prognosis of patients with ESCC. Phospholipase C epsilon-1 (PLCE1), 1KK alpha, 1KB alpha, p65, and p53 were highly expressed in ESCC tissues. The high expression level of PLCE1, 1KB alpha, and p53 showed a significant positive correlation with a short overall survival (P = .022, .009, and .024, respectively). This 3-biomarker panel (ie, PLCE1, IKB alpha, and p53) was found to be a predictor of ESCC, with a worse overall survival as each positive marker was added (hazard ratio, 1.553; 95% confidence interval, 1.166-2.067; P = .003). In another cohort (including 1922 esophageal endoscopic biopsy tissues), the lesions of 28 patients were aggravated. Three proteins (PLCE1, 12/28 [42.86%]; 1KB alpha, 16/28 [57.14%]; p53, 16/28 [57.14%]) were immunoreactive in patients with progressive disease. Our study identified and validated that this immunohistochemical biomarker panel of 3 proteins, consisting of PLCE1, IKB alpha, and p53, is not only independently associated with an unfavorable outcome for ESCC patients but also able to predict disease progression to precancerous lesions. (C) 2018 Elsevier Inc. All rights reserved.

引用

页码：7 / 17

页数：11